Teratogenic screening methods and their application to contraceptive products.
D000014:Abnormalities, Drug-Induced / Q000209:etiology*; D000818:Animals; D003276:Contraceptives, Oral / Q000009:adverse effects / Q000494:pharmacology* / Q000633:toxicity; D004353:Drug Evaluation, Preclinical; D004967:Estrogens / Q000378:metabolism*; D005260:Female; D005333:Fetus / Q000187:drug effects; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D000882:Haplorhini; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008431:Maternal-Fetal Exchange; D008599:Menstruation Disturbances / Q000139:chemically induced; D051379:Mice; D010063:Ovum / Q000187:drug effects; D011247:Pregnancy; D011372:Progestins / Q000378:metabolism*; D011817:Rabbits; D051381:Rats; D012098:Reproduction / Q000187:drug effects*; D013045:Species Specificity; D013997:Time Factors
D003276:Contraceptives, Oral; D004967:Estrogens; D011372:Progestins; D005640:Follicle Stimulating Hormone